Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

8th World Congress on Virology

San Antonio, USA

Joseph L. Mathew

Joseph L. Mathew

Postgraduate Institute of medical Education and Research, India

Title: Elimination of measles through routine vaccination in India (and other developing countries): Time to deliver old wine in a new bottle

Biography

Biography: Joseph L. Mathew

Abstract

Despite three decades of universal infant measles vaccination, India has the world’s largest measles burden. Vaccination in India (as in most developing countries) is timed at 9 months of age expecting infant protection through maternal (transplacental) antibodies till then, although this has not been proven scientifically. We conducted two prospective cohort studies in 2005 and 2015 (coinciding with 20 and 30 years of universal vaccination) to evaluate measles susceptibility in infants and to identify the appropriate age for vaccination. In these studies, anti-measles IgG antibodies were measured by quantitative ELISA in 60 and 130 infants at birth, 3 months, 6 months, and 9 months (prior to vaccination). Susceptibility was determined by antibody titre <200 mIU/ml. The first study (2005) showed that 0%, 12%, 51% and 100% infants were susceptible at birth, 3 months, 6 months and 9 months respectively. The second study (2015) confirmed susceptibility in 0%, 23%, 84%, and 100% infants. Preterm infants were more susceptible that term infants at 3 months and 6 months. These data suggest that most Indian infants become susceptible to measles well before the age of routine infant vaccination. Further the two time series showed that more infants were susceptible in 2015 than 2005; this could be due to greater proportion of mothers having vaccine-induced immunity than natural immunity. These data argue for earlier (rather than later) vaccination with measles vaccine in India and probably other developing countries also. This novel approach resembles serving old wine in a new bottle.